tradmap

TARA Protara Therapeutics, Inc.

$3.98 -1.97%

Healthcare · Biological Products, (No Diagnostic Substances)

Protara Therapeutics, Inc. (TARA) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $223 million. Shares last traded at $3.98, 49.7% below their 52-week high. Over the past year the stock is up 29.9%. Net profit margin is -1947.1%, below the peer median of 6.3%.

Market Cap
$223M
Shares Out
56.2M
EPS (TTM)
$-2.21
P/E Ratio
P/S Ratio
75.78
P/B Ratio
1.23
Dividend / Share
Dividend Yield
52-Week High
$7.90
52-Week Low
$2.77
Volume
36,215
Avg Vol (3m)
49,748.286

Performance

1W
+9.20%
1M
-8.20%
3M
-25.28%
6M
-26.66%
YTD
-26.18%
1Y
+29.90%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
39.80
SMA (50)
$4.83
SMA (200)
$5.26
Price vs SMA50
-17.66%
Price vs SMA200
-24.37%
ATR (14)
$0.27

Financials

Revenue
$3M
Net Income
$-57M
Gross Margin
Operating Margin
-2189.6%
Net Margin
-1947.1%
Return on Equity
-31.7%
Return on Assets
-29.9%
Current Ratio
15.69
Debt / Equity
0.06
Revenue Growth (YoY)

Latest reported annual period ending 2014-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.31 2026-05-13
FY 2025 $-1.34 2026-03-10
Q3 2025 $-0.96 2025-11-10
Q2 2025 $-0.65 2025-08-11
Q1 2026 $-0.29 2026-05-13
FY 2025 $-2.17 2026-03-10

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

TARA vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
75.78 / 5.21 med
+1354% premium
Net margin vs peers
-1947.1% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.